). (A) Synthesis route to access Epiblastin A-derived compounds substituted with alkoxy groups at position C4 (reaction condition a: (3-chlorophenyl) acetonitrile (1.2 eq), Cs 2 CO 3 (1.2 eq), THF, 65 o C, 3h). (B) Doseresponse curves of CK1inhibition upon Epiblastin A treatment at various ATP concentrations. Data represent mean values ± SEM of three independent measurements performed in duplicate. Black arrow indicates increasing concentrations of ATP. (C) Dose-response curves of CK1 inhibition upon Epiblastin A treatment at various ATP concentrations. Data represent mean values ± SEM of three independent measurements performed in duplicate. Black arrow indicates increasing concentrations of ATP. (D) Crystal structure of CK1 in complex with Epiblastin A and derivative 18, respectively. The chlorine and bromine atom in Epiblastin and derivative 18 are highlighted green and brown, respectively. Nitrogen and carbon atoms are shown in blue and red, respectively. The hydrogen bond network between the hinge region of CK1 and the 2,4-diaminopyrimidine unit of Epiblastin A and derivative 18 is shown as black dashed lines. Anomalous density measured at the bromine absorption edge (0.91883Å) for derivative 18 is represented as a blue mesh at a level of 3 I/σI. Figure 5 ). (A) Detection of CK1// protein levels in HeLa and HCT116 cell lines. Cell lysates were subjected to SDS-PAGE followed by transfer of proteins to a PVDF membrane. CK1, CK1 and CK1 were detected using primary anti-CK1, anti-CK1 and anti-CK1 antibodies and a secondary antibody coupled to horseradish peroxidase. Tubulin was visualized as loading control for CK1 using anti-/-tubulin antibody. GAPDH was employed as loading control for CK1/ using anti-GAPDH antibody. For both controls, the secondary antibody was coupled to horseradish peroxidase. Data are representative of three independent experiments. (B) Proteins identified to interact with Epiblastin A (100 μM) using 10 μM ActivX TM ATP probe in HCT116 cell lysate. The proteins marked with X were statistically significant by the median test analysis, while the targets labeled with XX were very significant under the same statistical parameters; x min/x min suggests the incubation time of the HCT116 cell lysates with Epiblastin A and ActivX TM ATP probe, respectively. Data are representative of three independent experiments. (C) Dose-response curves of STK10 inhibition upon Epiblastin A treatment determined by means of radiometric-based assay at Km-ATP value. Data represent mean values ± SEM of three independent measurements. Determined IC 50 value ± SEM was generated by fitting the data with three parameter nonlinear regression analysis. Figure 5 ). Dose-response curves for inhibition of BRSK1 (A), EEF2K (B), EGFR (C), MKNK2 (D) and RIPK2 (E) respectively by Epiblastin A evaluated at Km-ATP of each kinase. Data are mean values of three independent measurements performed at Eurofins by mean of radiometric-based assay. (F) Determined IC 50 values ± SEM were generated by fitting the data with three parameter nonlinear regression analysis. /cyclin T1  87  CK1α  78  CK1γ1  98  CK1γ2  95  CK1γ3  110  CK1δ  28  CK1ε  60  CK2  95  CK2α2  109  CLK1  67  CLK2  79  CLK3  105  CLK4  69  c-Raf  91  cSRC  97  FAK  105  Fer  111  FGFR1  93  FGFR2 104
Figure S3. Identification of potential targets engaged by Epiblastin A in HCT116 cell lysates (related to

Figure S4. Inhibition of different kinases by Epiblastin A as revealed by in vitro profiling (related to
Kinase activity [%]
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Supplemental Experimental Procedures
Chemistry
Materials
All the chemicals mentioned in the current study were purchased from Alfa Aesar and Sigma Aldrich and used as provided, without any further purification. Analytical thin-layer chromatography (TLC) was executed on silica gel aluminium plates with F-254 indicator (Merck, Germany). Compounds were visualized on the TLC plates by irradiation with UV light. Acros 60A (particle size 0.035 -0.070) silica gel was employed for the column chromatography purification of the derivatives reported in this study. Compound characterization by means of 1 H-and 13 C-NMR analyses was performed on Bruker DRX400 (400 MHz), Bruker DRX500 (500 MHz) and INOVA500 (500 MHz). Deuterated DMSO (DMSO-d6) was used as internal standard. Signal characterization is described using the next abbreviations: s (singlet), d (doublet), dd (double doublet), dt (double triplet), t (triplet), q (quartet) and m (multiplet). Coupling constant values are presented in Hertz (Hz). Fourier transform infrared spectroscopy (FT-IR) characterizations were recorded with a Bruker Tensor 27 spectrometer (ATR, neat) and are reported in terms of frequency of absorption (cm -1 ). Chemical yields refer to isolated and pure substances. High resolution mass (HRMS) spectra were recorded on a LTQ Orbitrap mass spectrometer coupled to an Accela HPLC-System (HPLC column: Hypersyl GOLD, 50 mm × 1 mm, 1.9μm). Solvent mixtures for thin layer chromatography are depicted as volume : volume. PE is the abbreviation for petroleum ether.
Derivatives 34-36 (entries 34-36, Table 1 ) were synthesized according to literature procedures [1] . Starting materials 2 and 3 (entries 2-3, Figure 3A ) were synthesized following a procedure already reported in the literature [2] . Derivatives 37 and 39 (entries 37 and 39, Table 1 ) were generated using a known synthetic route [3] . Starting materials 41-49 (entries 41-49, Figure S2A ) were generated starting from 4-chloro-2,6-diaminopyrimidine following a two-step procedure previously reported [4] . The confirmation of the identity and purity of the compounds mentioned in the literature was assessed by 1 Table 1 , except for the compounds already mentioned above, was performed using a slightly modified workup procedure than originally reported in the literature [3] , [5] , [6] , [7] . The derivatives not mentioned in the literature are characterized below by means of 1 H-and 13 C-NMR, HRMS and FT-IR.
H-NMR and HPLC-MS analyses only. Synthesis of the derivatives shown in
General procedure for the synthesis of derivatives 50-59 (entries 50-59, Figure S2A ) Compound 50: (3-chlorophenyl)acetonitrile (0.5 mmole, 1.2 eq) was dissolved in 3 mL dry THF and then Cs 2 CO 3 (0.5 mmole, 1.2 eq) was added followed by 4-ethoxy-5-nitroso-2,6-diaminopyrimidine (0.4 mmole, 1.0 eq). The mixture was stirred at 65ºC for 3 hours. After solvent evaporation, the mixture is purified using column chromatography on silica using acetone : petroleum ether 4:1 (R f = 0.12) furnishing 55 mg of an yellowish brown solid (yield = 44 %).
Biology Materials
Human basic fibroblast growth factor (bFGF) was purchased from Peprotech (Germany). Human leukemia inhibitory factor (LIF) was produced in-house [8] . KO-DMEM was acquired from Invitrogen. CHIR99021 and PD0325901 were purchased from Tocris Bioscience. Hoechst 33258 was obtained from Sigma. 4',6-diamidino-2-phenylindole (DAPI) was purchased from Invitrogen. Dulbecco's Modified Eagle's medium (DMEM), sodium pyruvate, penicillin / streptomycin, non-essential amino acids and trypsin were purchased from PAN Biotech (Germany). Fetal bovine serum was purchased from Invitrogen (Germany). Cell culture flasks were purchased from Sarstedt (Germany). Anti-CK1 (Abcam, mouse, ab85320), anti-CK1 (BD Biosciences, mouse, 610445) and anti-CK1 (Santa Cruz, goat, C-19, sc-6477) antibodies have been used according to the vendor's recommended protocols. Stk10 antibody (Santa Cruz, mouse, D-6, sc-398083) was purchased from Santa Cruz Biotechnology and used according to the vendors indications. 384-well white plates with clear bottom were purchased from Corning (Germany). Phosphate buffered saline (PBS) tablets were purchased from Jena Bioscience (prod no AK-102P-L, Jena, Germany). Protease and phosphatase inhibitor cocktails were obtained from Roche (Germany). Kinase assay, target engagement and chemical proteomics experiments were performed with MiliQ water. LoBind Tubes (Eppendorf, Germany) were used for target engagement and proteomics experiments. HCT116 cell lysis protocol was performed under sterile conditions for chemical proteomics experiments only.
Cell lines
For testing reprogramming efficiencies of the pteridine-based derivatives the E3 EpiSC-GOF18 cell line was used which is derived at E5.5 from (C57BL/6 X DBA/2) X 129/Sv. In this case the Oct4 transgene corresponds to a 10 kbp fragment (genomic Oct4 fragment 18kbp: GOF18) [9] . EpiSC medium (MEF-conditioned) contained Knockout(KO)-DMEM, 20 % Knockout -Serum Replacement (KOSR), 1 x L-glutamine, penicillin / streptomycin, non-essential amino acids, 100 M 2-mercaptoethanol and 5 ng / mL bFGF (before and after conditioning over MEFs). Cells were cultured on fetal calf serum (FCS)-coated dishes and passaged with Accutase ® (Life Technologies). mESCs or reverted EpiSCs were grown on MEFs using mESC medium containing Knockout (KO)-DMEM, 20 % Knockout -Serum Replacement, 1 x L-glutamine with penicillin / streptomycin, non-essential amino acids, 100 M 2-mercaptoethanol and 2000 U / mL LIF. The human colorectal carcinoma cell line HCT116 (DSMZ-No. ACC-581) and human cervical carcinoma HeLa (DSMZNo. ACC-57) cells were purchased from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Germany). All cell lines were cultured following the growth media indicated by the vendors at 37°C in a 5 % CO 2 humidified atmosphere.
Quantitative real-time PCR (qPCR)
Total RNA from cultured cells was isolated using the RNeasy Mini/Micro Kit (Qiagen) following the manufacturer's instructions. To generate cDNA, total RNA was reverse transcribed using M-MLV reverse transcriptase and oligo-dT primer. The knockdown efficiency for each CKI isoenzyme was assessed by means of quantitative PCR (qPCR) using SYBR Green PCR master mix (Biorad) and the Applied Biosystems 7500 Real-Time PCR instrument. The following oligonucleotides were used to detect mouse Csnk1a/d/e or Actb as a reference gene: Csnk1a1; 5'-TATTCCGCATCCTTTTCAGG-3' / 5'-TCTGCTGCTTCTCTTCCACA3'; Csnk1d; 5'-ATGCCATTTGGGTTTGTCAT-3'/ 5'-CACCACACCTTTCTGGAGGT-3'; Csnk1e: 5'-GCTCGAATGTGTGAAGACGA-3' / 5'-CGTCTTGAGGCTGAACTTCC-3'; Actb: 5'-ACTGCCGCATCCTCTTCCTC-3' / 5'-CCGCTCGTTGCCAATAGTGA-3'. The relative expression levels were calculated using the 2 -ΔΔCT method. [10] shRNA-mediated knockdown of CK1 isoenzymes Lentiviral shRNA constructs were purchased from GE Dharmacon. To produce lenti-viruses, HEK293 cells were plated at a density of 8 x 10 6 per 10-cm dish. On the next day, cells were transfected with 3 μg psPAX2 (Addgene #12260), 1.5 μg pMD2.G (Addgene #12259) and 4.5 μg lentiviral vector using 27 μl Fugene 6 in 600 µl Opti-MEM. Virus-containing supernatants were collected 48 h later and filtered through a 0.4-µm PVDF filter, concentrated and re-suspended in Knockout DMEM and stored at -80°C until use. The epiblast stem cells were infected with 5 µl of concentrated viruses and infected cells were selected with puromycine (1µg/ml). TRC CK1 shRNA TRCN0000023770 (clone ID) Mature Antisense: ATTCAGAAGGATAGCCCTTGC (Sequence) TRC CK1 shRNA TRCN0000023808 Mature Antisense: AATATGCTGGTGTGTGCGGGC TRC CK1 shRNA TRCN0000023798 Mature Antisense: TACAGTTTGCTCTCGTACAGC Preparation of cell lysate for detecting CK1// HeLa and HCT116 cells were cultured up to 80-85 % confluency. Growth media was removed, and cells were washed and collected by scrapping in ice-cold PBS. Cells were centrifuged for 5 min at 400 x g and lysed for 10 min on ice in a lysis buffer containing 50 mM PIPES (pH 7.4), 50 mM NaCl, 5 mM MgCl 2 , 5 mM EGTA, 0.1 % NP40, 0.1 % Triton X-100, 0.1 % Tween  20 and freshly added 0.1 % 2-mercaptethanol EDTA-free protease inhibitor cocktail (Complete EDTA free, Roche, Germany) and phosphatase inhibitors (PhosphoSTOP, Roche, Germany). Lysates were homogenized by passing them five times through 20G and 24G needles, respectively. Cellular debris was separated by centrifugation at 12000 x g for 20 min at 4°C. Clear cell lysates were frozen at -80°C. Protein concentration was determined using the Bradford reagent (Bio-Rad, Germany).
Immunoblotting
Cells were collected by scrapping and lysed following the procedure described above. Protein concentration was determined using the Bradford reagent (Bio-Rad, Germany). Samples were adjusted to the same protein concentration prior to denaturation in Laemmli buffer at 95°C for 8 min. Proteins were then separated by means of sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred by means of semidry electroblotting to a polyvinylidene difluoride (PVDF) membrane (Thermo Scientific, Germany). Membranes were blocked using 5 % non-fat dry milk in Tris-buffered solution (10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1 % Tween ® 20 for CK1 and 20 mM Tris-HCl (pH 7.6), 140 mM NaCl, 0.05 % Tween ® 20 for CK1, CK1 and Stk10) and were then incubated with the appropriate primary antibodies, diluted in blocking solution (CK1 1:300, CK1 1:5000, CK1 1:2000 and Stk10 1:200) overnight at 4°C. Anti--tubulin (for CK1) or anti-GAPDH (for CK1/) antibodies were employed to detect -tubulin or GAPDH as loading controls. Detection of bound primary antibodies was performed by incubating with appropriate secondary antibodies coupled to horseradish peroxidase (HRP, Pierce, USA) and SuperSignal West Pico or Femto Maximum Sensitivity Substrate (Pierce, USA). For reprobing, membranes were stripped in Restore Western Blot Stripping Buffer (ThermoScientific, USA) for 10 min at room temperature according to the vendor's instructions.
Plasmid construction, protein expression and purification
Fully sequenced human cDNA constructs for CK1 (former cat. no. MHS4771-202829011; replaced by MHS6278-202829011, clone ID 3546633, accession no. BC003558) and CK1 (cat. no. MHS6278-202830217, clone ID 3937782, accession no. BC006490) were purchased from Open Biosystems -Dharmacon (GE Healthcare). The nucleotide sequence corresponding to amino acids 1-294 of the human CK1 and CK1 cDNA was amplified using the oligonucleotides: 5'-GAAGTTCTGTTTCAGGGTCCCATGGAGCTGAGAGTCGGGAACA-3' 5'-CTTTGTTAGCAGCCGGATCATTATTTGAGCATGTTCCAGTCGAACACG-3' for CK1 and 5'-GCGAACAGATCGGTGGTATGGAGCTACGTGTGGGGAAC-3' 5'-ATTTCAGCATGTTCCAGTCAAAGACGTA-3' for CK1 and subsequently subcloned in pET19-nHis-3C for CK1 and pOPIN-His-Sumo for CK1.
pET19-nHis-3C-CSNK1D_1-294 and pOPIN-His-Sumo-CSNK1E_1-294 were transformed in the E. coli strain BL21 DE3 RIL(K+). Bacteria were grown in SB medium (3.2 % peptone, 2 % yeast extract and 0.5 % NaCl) at 37°C. Expression was induced with 400 M IPTG at OD 600 of 0.6. Cells were grown at 25°C for 18 h. Harvested cells were suspended in lysis buffer (50 mM Tris, pH 8.0, 400 mM NaCl, 5 % glycerol, 0.1 % Triton X-100, 1 mM DTT, 5 mM imidazol and protease inhibitors) and lysis was performed by sonication. After centrifugation the supernatant was loaded on a Ni-NTA column (Qiagen). After washing with 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 % glycerol and 5 mM imidazol, proteins were eluted with 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 % glycerol and 30 mM imidazol. In collected fractions proteins were digested using Prescission protease / Sumo protease and were further purified by size exclusion chromatography using a Sephadex G200 column with 25 mM Hepes pH 7.0, 150 mM NaCl, 2 mM TCEP, 10 mM MgCl 2 and 5 % glycerol for CK1 and 25 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM TCEP, 10 mM MgCl 2 and 5 % glycerol for CK1. For both proteins, the buffer was exchanged to CK1 dilution buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 0.25 mM DTT, 25 % glycerol). To this end, Zeba Spin Desalting Column (7K MWCO, 2 mL; Thermo Scientific) was centrifuged at 1000 x g for 2 min at room temperature. The column was equilibrated three times with 1.2 mL ice-cold CK1 dilution buffer at 1000 x g for 2 min at room temperature. After the final centrifugation step, the kinase containing fraction was added and centrifuged for 2 min at 1000 x g and room temperature. The newly obtained kinase containing solution was collected and protein concentration was determined using the Bradford reagent (Bio-Rad Protein Assay Kit I, Bio-Rad, cat no 5000001) and adjusted to approx. 1 g / L. Proteins were snap-frozen in liquid nitrogen and stored at -80°C.
Crystal structure determinations
Crystals of CK1 were obtained at 4°C in hanging drops containing 0.1 M Li 2 SO 4 , 0.7 -0.8 M Na-K tartrate and 0.1 M CHES (pH 9.5). Protein concentration used was 7.45 mg / mL in CK1 dilution buffer. Crystals appeared after 21 days as small ellipsoids and were mounted in a thin film of mother liquor without additional cryo protectant. Structures of CK1 in complex with Epiblastin A (entry 15, Table 1 ) and derivative 18 (entry 18, Table 1 ) were obtained by soaking crystals overnight in mother liquor containing 4 mM of Epiblastin A and derivative 18 (40 % DMSO concentration in the final drop). The crystals belonged to the space group 152 (P3 1 21) with a unit cell parameters of a = b = 64.5 Å, c = 151.8 Å,  =  = 90˚,  = 120˚ and one molecule in the asymmetric unit. Diffraction data was collected at PXII at Swiss Light Source (SLS) at Paul-Scherrer-Institute, Villigen, Switzerland using a Pilatus 6M detector. The data was processed and scaled using XDS / XSCALE [11] and solved by molecular replacement with PHASER [12] from the CCP4-suite [13] using PDB entry code 3UYS as template. Model building and refinement was carried out using REFMAC5 [14] and coot. [15] The data collection and refinement parameters of the apo-CK1 and CK1 in complex with Epiblastin A and derivative 18 crystal structures can be found in Table S7 .
Cell lysate preparation for target engagement and chemical proteomics HCT116 cells were grown up to 80-90 % confluency. Cells were washed and collected by scraping using icecold PBS. Cells from multiple T175 flasks were combined and centrifuged for 5 min at 500 x g and 4°C. Cell pellets were either directly frozen (and stored at -80°C) or subsequently lysed in ice-cold Pierce IP Lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP-40 and 5 % glycerol) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, prod. no. 78440) for 10 min on ice. To assure complete cell lysis samples were gently vortexed every three min until a homogeneous mixture was obtained. The resulting homogenate was centrifuged for 5 min at 16000 x g and 4°C and supernatant were carefully transferred into a new vial. For the buffer exchange procedure, the protocol suggested by the vendor was applied. Zeba Spin Desalting Columns (7K MWCO, 5 mL; Thermo Scientific, prod. no. 89891) were centrifuged at 1000 x g for 2 min at room temperature. The column was equilibrated with ice-cold Kinase buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 0,1% Triton X-100) and centrifuged at 1000 x g for 2 min at room temperature prior to addition of the cell lysate and centrifugation for 2 min at 1000 x g and room temperature. The buffer-exchanged lysate was and the protein concentration was adjusted to approximately 2 mg / mL with ice-cold Kinase buffer. Lysates were subsequently stored at -80°C.
Kinase profiling at Eurofins (former Milipore)
Single-point measurement analyses of Epiblastin A against a panel of 123 kinases was performed at Eurofins (former Milipore) using a radiometric-based assay and K m -ATP (K m is defined as the concentration of ATP that allows half-maximal reaction velocity) concentration for each individual kinase. Dose-dependent investigations of Epiblastin A against BrSK1, Egfr, eEF2k, Mknk2, Ripk2 and Stk10 have been performed under the same experimental setup, i.e. at K m -ATP value. Half-maximal inhibitory concentrations (IC 50 ) were obtained by fitting the obtained data with three parameter nonlinear regression analysis using GraphPad Prism version 6.00 for Windows (GraphPad Software, USA). For more details related to the experimental conditions employed at Eurofins please consult the following website: http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitropharmacology/kinases/biochemical.aspx Determination of CK1/ activity using the KinaseGlo ® Plus luminescent assay A stock solution of 5 % DMSO (BioReagent for molecular biology, Sigma Aldrich) in water was prepared. The CK1 substrate peptide RRKDLHDDEEDEAMSITA (Jena Bioscience, cat. no. PE-206, 2 mM stock solution in water) was diluted in water to a final concentration of 250 μM. CK1 or CK1 kinases were diluted with CK1 dilution buffer to 50 ng / L. In addition, fresh Reaction buffer was prepared containing 250 mM Tris-HCl (pH 7.5), 50 mM MgCl 2 , 5 mM DTT and 0.5 mg / mL bovine serum albumin (BSA). Compounds were serially diluted in 5 % DMSO solution to the desired concentrations (maximal concentration employed in the assay was 50 M). Additional samples included blank sample containing Reaction buffer, water and CK1 / CK1 kinase and control sample containing Reaction buffer, CK1 substrate peptide and CK1 / CK1 kinase. CK1 substrate peptide, Reaction buffer and CK1 / CK1 kinase stock solutions were mixed in 1:1:1 ratio. 6 μL of this mixture was added to 384-well plates (384 well low volume white round bottom polystyrene NBS™, Corning ® , prod. no. 3673). 2 L of the test compound stock solutions were subsequently added to the wells. The same volume of the 5 % DMSO solution was added to the blank and control samples, respectively (final DMSO concentration in the assay was 1 %). The content of the plate was centrifuged for 1 min at 750 x g and room temperature. The plate was incubated under rotation / shaking at room temperature for 5 min, followed by 25 min incubation at room temperature. The kinase reaction was initiated by adding 2 L ATP (Ultra Pure ATP, Promega, product no V703A-C, 100 mM stock solution in water) from a 50 M stock solution in water. The content of the plate was centrifuged for 1 min at 750 rpm and room temperature, followed by shaking for 5 min at room temperature and incubation at room temperature for 55 min. Afterwards, 10 L of the Kinase-Glo ® Plus reagent (Promega, cat. no. V3771) was added to each well and the plate was incubated at room temperature for 5 min. Luminescence was recorded on an Infinite ® M200 plate reader (Tecan, Austria) (integration time 1000 ms, settle time 5 ms).
CK1/ kinase activity (% of control) was calculated as follows:
Kinase activity (%) = ((<luminescence (blank sample)> -<luminescence (compound sample)>) / (<luminescence (blank sample)> -<luminescence (control sample)>)) x 100.
Half-maximal inhibitory concentrations (IC 50 ) were generated by fitting the obtained data with three parameters nonlinear regression analysis using GraphPad Prism version 6.00 for Windows (GraphPad Software, USA).
CK1 profiling at Reaction Biology
Single-point measurements analyses and subsequent dose-dependent investigations of selected pteridine derivatives for inhibition of CK1 were performed at Reaction Biology (USA) using a radiometric-based assay and ATP concentration of 10 M. For more details related to the experimental conditions employed please consult the following websites: http://www.reactionbiology.com/webapps/site/KinaseDetail.aspx http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx Half-maximal inhibitory concentrations (IC 50 ) were generated by fitting the obtained data with three parameter nonlinear regression analysis using GraphPad Prism version 6.00 for Windows (GraphPad Software, USA).
Detection of target engagement using the ActivX TM ATP probe HCT116 cell lysate (approx. 1 mg total protein) was thawed on ice prior to activation by adding 10 L of 1 M MgCl 2 stock solution to each sample. Samples were vortexed gently and incubated for 1 min at room temperature. 1 % of the entire volume was removed and replaced by the same volume of DMSO (BioReagent for molecular biology, Sigma Aldrich) or Epiblastin A stock solution in 100 % DMSO, respectively (0.1, 1 and 10 mM Epiblastin A initial stock solutions were used to yield 1, 10 and 100 M Epiblastin A final concentration in the cell lysate; DMSO content in all samples was 1 %). Samples were gently vortexed and incubated at room temperature for 10 minutes. Two vials containing 12.6 g of the ActivX TM ATP probe each (Life Technologies, cat. no. 88311; stored at -80°C) were pre-equilibrated at room temperature. 22.5 L water was added to one vial and the content from the first vial was transferred to the second vial (final solution contains 2 x 12.6 g ActivX TM ATP probe dissolved in 22.5 L water). 5 L from the final solution was transferred to the DMSO and Epiblastin A-treated samples, respectively. The content was gently mixed and incubated at room temperature for 10 min. The solution was diluted 1:2 in 8 M urea stock solution in Pierce IP lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP-40 and 5 % glycerol), followed by the addition of 45 µL of high capacity streptavidin agarose resin (50 % slurry; Pierce™ Streptavidin Agarose, cat no 20347). The resulting mixture was incubated for 1 hour at room temperature with overhead rotation (speed 10; Rotator SB3, Stuart). Samples were centrifuged at 1000 x g and room temperature for 1 min. The supernatant was carefully replaced by the same volume of 4 M urea in Pierce IP lysis buffer (same volume that has been added in the case of 8 M urea dilution; see previous step). This mixture was transferred into a spin column and centrifuged at 1000 x g and room temperature for 1 min. The washing step with 4 M urea in Pierce IP lysis buffer was repeated twice. Finally, 45 L of a 2 x Laemmli buffer (100 mM Tris pH = 6.8, 7 % SDS, 200 mM DTT, 0.014 % Bromphenol blue) was added to the separated beads on the spin column. The spin column was closed, placed in a new vial and proteins were denatured for 10 min at 95ºC under shaking. The vials were left to cool down at room temperature and the content of the spin column was collected in a new vial at 5000 x g for 3 min at room temperature. Target engagement experiments were carried out by varying compound incubation time and / or the incubation time for the ActivX TM ATP probes, respectively with respect to each kinase. Samples were then analyzed by means of immunoblotting or mass spectrometry.
Chemical proteomics experiment based on the ActivX TM ATP probe Same protocol was applied as previously described for the detection of target engagement. In addition, a bovine serum albumin (BSA) control was prepared by adding 1 L of 5 pmol / L BSA stock solution in a separate vial together with 45 L of the 2 x Laemmli buffer. A total of 7 samples were boiled for 10 min at 95ºC with shaking (500 rpm) (Thermomixer ® comfort, Eppendorf). Samples were left to cool down at room temperature and centrifuged in new vials at 5000 x g for 3 min at room temperature. Samples were loaded onto Mini-Protean TGX precast gels (4-20 %). 2 x Laemmli buffer was loaded in a separate well as an additional control for the proteomics procedure. Proteins were separated for 20 min at 80 V. The gel washed overnight with a mixture containing water, EtOH (ethanol) and acetic acid in a 5:4:1 ratio. The gel was cut in pieces with a scalpel and transferred into new LoBind tubes. Gel pieces were washed with 200 L washing solution 1 (WS1, 25 mM ammonium bicarbonate : acetonitrile, 3:1), tubes were briefly centrifuged and incubated for 30 min at 37°C with shaking at 600 rpm. Supernatants were removed and the procedure was repeated by adding 200 L washing solution 2 (WS2, 25 mM ammonium bicarbonate : acetonitrile; 1:1) under the same conditions and incubation for 15 min. The solution was removed and 200 L reducing solution was added (50 mM dithiothreitol in 25 mM ammonium bicarbonate, always freshly prepared). Vials were briefly centrifuged and incubated for 45 min at 37°C. The reducing solution was then exchanged for 200 L alkylating solution (55 mM iodacetamide in 25 mM ammonium bicarbonate). Samples were briefly centrifuged and the content was incubated under shaking for 1 hour at room temperature in the dark. The alkylating solution was removed and gel pieces were washed twice for 15 minutes with WS2 at room temperature. Afterwards, the solutions were removed as completely as possible. The gel pieces were dehydrated by adding 100 L acetonitrile for 10 minutes at room temperature. At this stage the gel turned white. The acetonitrile was removed and the gel pieces were left to dry for 10 min. Subsequently, 50 L digest solution was added (0.01 g / L Trypsin in 25 mM ammonium bicarbonate solution). Vials were briefly centrifuged and incubated for 15 minutes at room temperature. 75 L 25 mM ammonium bicarbonate was subsequently added and vials were again briefly centrifuged and incubated overnight at 30°C with shaking (350 rpm). 10 L 10 % trifluoroacetic acid (TFA) was added to the gel pieces and vials were briefly centrifuged and incubated for 30 min in a sonicator bath on ice. 75 L acetonitrile was added to the gel pieces, vials were briefly centrifuged and were left to shake for 15 minutes at 350 rpm at room temperature. The supernatant was transferred into new vials and 75 L acetonitrile was added to the gel pieces, the vials were briefly centrifuged and subsequently incubated for additional 15 minutes at room temperature with shaking (350 rpm). Both acetonitrile containing fractions were combined and vacuum concentrated. Samples were stored at -20°C.
Mass spectrometric analysis
For protein identification tryptic peptides were separated and analyzed by nano-HPLC/MS/MS. The separations were carried out on UltiMateTM 3000 RSLCnano system (Dionex, Germany). The MS and MS/MS experiments were carried out on a Q Exactive™ Hybrid Quadrupole-Orbitrap Mass Spectrometer equipped with a nano-spray source (Nanospray Flex Ion Source, Thermo Scientific). All solvents were LC-MS grade. The lyophilized tryptic peptides were dissolved in 20 L 0.1 % TFA in water. 3 L of sample were injected onto a pre-column cartridge (5 m, 100 Å, 300 m ID * 5 mm, Dionex, Germany) using 0.1 % TFA in water as eluent with a flow rate of 30 L/min. Desalting was performed for 5 min with eluent flow to waste followed by backflushing of the sample during the whole analysis from the pre-column to the PepMap100 RSLC C18 nano-HPLC column (2 m, 100 Å, 75 m ID × 25 cm, nanoViper, Dionex, Germany) using a linear gradient starting with 95 % water containing 0.1 % formic acid / 5 % acetonitrile containing 0.1 % formic acid and increasing to 70 % water containing 0.1 % formic acid / 30 % acetonitrile containing 0.1 % formic acid after 95 min using a flow rate of 300 nL / min. The nano-HPLC was online coupled to the Quadrupole-Orbitrap Mass Spectrometer using a standard coated SilicaTip (ID 20 μm, Tip-ID 10 μM, New Objective, Woburn, MA, USA). Mass range of m/z 300 to 1650 was acquired with a resolution of 70000 for full scan, followed by up to ten high energy collision dissociation (HCD) MS / MS scans of the most intense at least doubly charged ions. Data evaluation was performed using MaxQuant software [16] (v.1.4.1.2) including the Andromeda search algorithm and searching the human reference proteome of the Uniprot database. The search was performed for full enzymatic trypsin cleavages allowing two miscleavages. For protein modifications carbamidomethylation was chosen as fixed and oxidation of methionine and acetylation of the N-terminus as variable modifications. The mass accuracy for full mass spectra was set to 5 ppm and for MS/MS spectra 20 ppm. The false discovery rates for peptide and protein identification were set to 1 %. Only proteins for which at least two peptides were quantified were chosen for further validation. Relative quantification of proteins was carried out using the labelfree quantification algorithm implemented in MaxQuant. All experiments were performed in technical triplicates. Label-free quantification (LFQ) intensities were logarithmized (log2) and proteins which were not three times quantified in at least one of the groups were filtered off. Missing values were imputed using small normal distributed values and a median test was performed. Proteins which were statistically significant outliers were considered as hits. (signals depicted in Italic suggest the presence of the structure 2 in solution also)
